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Abstract
Finding a soft tissue mass in the superficial regions is a common event in daily clinical practice. Correct management of
the diagnostic process is crucial to avoid blunders. Diagnosis is posed by pathology, although both imaging and a better
understanding of the cellular and molecular mechanisms play an important a role in the characterization, staging and
follow-up of soft tissue masses. Cellular and molecular mechanisms can explain either the development of
chemo-resistance and the underlying pre- and post-surgery metastasis formation. These are mandatory to
improve prognosis and unveil novel parameters predicting therapeutic response. Imaging mainly involves
ultrasound and MR and is fundamental not only in diagnosis but also in the first step of therapy: the biopsy.
Novel imaging techniques like Ultrasound Elastosonography, Dynamic Contrast-Enhanced MR imaging (DCE),
Diffusion Weighted MR imaging (DWI) and MR Spectroscopy (MRS) are discussed. This paper aims at reviewing
and discussing pathological methods and imaging in the diagnosis of soft tissue masses underscoring that the
most appropriate treatment depends on advanced molecular and radiological studies.
Keywords: Sarcoma, Biomarkers, Signalling pathways, Molecular imaging, Magnetic resonance imaging,
Ultrasound elastosonography
Background
Soft tissue sarcomas (STS) represent 1 % of all malignant
tumours [1, 2] with more than 50 histological subtypes
associated with distinctive clinical and/or molecular
profiles, prognosis and response to tailored therapy. STS
are mostly benign with an incidence of 100 to 1 and
75 % involve limbs. Malignancy increases with age, and
is significantly higher in adult patients compared to
children where 75 % of masses are benign [3].
An important percentage of malignant lesions rapidly
metastasize leading to a poor outcome. Despite advances
in therapy, high-grade STS are associated with a 50 %
mortality rate [4, 5].
Surgical removal of tumours in association with radi-
ation and chemotherapy has brought an increase in the 5-
year disease-free survival of localized STS, while clinical
outcome of patients with advanced or metastatic disease
remains strongly unfavorable. Metastasis are usually
located in the lung. However, a significant amount of STS
are associated with bone metastases and this along with
adverse histological and radiological indicators are consid-
ered predictive factors for mortality [6, 7]. In order to
improve the sarcoma grading and prognosis, Chibon et al.
[8] established a “complexity index in sarcoma” (CINSARC)
by relating gene expression to mitosis and chromosome
management. Recently, multicentric studies confirmed
the relationship between multidrug resistance factors
and STS patient survival [9].
Based on cytogenetic and genomic data, STS are di-
vided into “STS with simple genomics” (SSG), displaying
specific genetic alterations such as chromosome translo-
cations, and “STS with complex genomics” (SCG), with
nonspecific multiple genomic alterations and a high gen-
omic instability [10]. In the SSG group (Table 1) fusion
gene products may be useful in differential diagnosis
[11]. The majority of these chimeric proteins are tran-
scription factors that cause dysregulation of target
genes and this makes it difficult to apply new thera-
peutic tools such as antibody therapy. However, some
fusion genes induce activation of tyrosine kinase end-
points or autocrine growth factors that are suitable
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for pharmacologic inhibition [12]. The pathobiology
of SCG tumours (Table 1) is still unknown, and poses
challenges in diagnosis and therapeutic management.
To date, high histological grade, deeply seated and greater
than 5 cm in size are universally established risk factors for
STS metastatic progression. In these cases magnetic reson-
ance (MR) imaging can help define lesions with an atypical
appearance [13]. Imaging is of outstanding importance
particularly in STS where novel techniques like ultrasound
elastosonography, dynamic contrast-enhanced MR imaging
(DCE), diffusion weighted MR imaging (DWI) and MR
spectroscopy (MRS) are essential for a better understanding
of the lesion.
In contrast molecular biomarkers for STS patient strati-
fication useful as targets for tailored molecular therapies
are not yet well documented.
Given these evidences, a multidisciplinary approach
combining molecular aspects with pathological, radio-
logical and clinical features is required to understand
specific defects leading to metastasis formation and de-
velopment of chemo-resistance in distinct STS subsets.
Review
Cell signalling pathways and molecular targets
Sarcomas are a heterogeneous group of mesenchymal
tumours where molecular studies demonstrated biological
differences even in tumours with the same diagnosis that
share many histological and MR imaging features, but have
a different prognosis and therapeutic strategies [11, 13].
This requires a new classification that relies on the
definition of distinct biological entities followed by the
need to stratify high-risk patients for whom more appro-
priate therapies should be planned. In the setting of ma-
lignant phenotype different cellular signalling pathways
drive metastatic progression converging into common
interconnection endpoints. Although consensus is emer-
ging that treatment should be histology-driven, recent
studies suggest tailored therapies against these common
molecular targets [14–16] identifying the effects of gen-
etic aberrations on downstream signalling pathways with
activation of key intracellular mediators that may repre-
sent targets for biological therapies.
Few highly recurrent driver genes have been described
in sarcomas with high genomic complexity [17], including
defects in oncosuppressor genes RB1 and PTEN, mutations
in TP53 and homozygous deletions of p16/CDKN2A, a
cyclin-dependent kinase inhibitor [18, 19]. Numerous gains
and losses of chromosome DNA sequences characterize
poorly differentiated sarcomas as leiomyosarcoma (LMS),
pleomorphic rhabdomyosarcoma (RMS), pleomorphic
liposarcoma (LPS), undifferentiated pleomorphic sarcoma
(UPS) and are accompanied by rearrangements and muta-
tions that trigger activation of downstream pathways and
cell cycle perturbation [17–20]. In agreement with these
data, a comprehensive analysis of a large series of sarcomas
with complex genomics recognized multiple interplays
between RB1, PTEN, DKK1 signalling pathways controlling
the oncogenesis process and cell proliferation [10]. Aberra-
tion in TP53 and p16/CDKN2A oncosuppressor genes,
Table 1 Soft tissue sarcoma molecular subtypes
STS with simple genomics More frequent translocations STS with complex genomics
Ewing sarcoma family (ES/PNET) t(11;22)(q24;q12) Malignant peripheral nerve-sheath tumor (MPNST)
Desmoplastic Small Round Cell Tumor (DSRCT) t(11;22)(p13;q12) Undifferentiated Pleomorphic Sarcoma (UPS)
Alveolar soft part sarcoma t(X;17)(p11;q25) Fibrosarcoma (FS)
Congenital fibrosarcoma t(12;15)(p13;q25) Pleomorphic Liposarcoma (PLPS)
Myxoid Liposarcoma (LPS) t(12;16)(q13;p11) Leiomyosarcoma (LMS)
Malignant melanoma of soft parts t(12;22)(q13;q12) Embryonal/Pleomorphic RMS (ERMA/PRMS)
Synovial sarcoma (SS) t(X;18)(p11.23;q11) Angiosarcoma Myxofibrosarcoma (MFS)
Alveolar Rhabdomyosarcoma (ARMS) t(2;13)(q35;q14) Osteosarcoma (OS)
DermatoFibroSarcoma Protuberance (DFSP) t(17;22)(q22;q13)
Epithelioid hemangioendothelioma t(1;3)(p36.3;q25)
Mesoblastic nephroma t(12;15)(p13;q25)
Clear cell sarcoma (CCS) t(12;22)(q13;q12)
Angiomatoid fibrous histiocytoma t(12;16)(q13;p11)
Low grade fibromyxoid sarcoma t(7;16)(q32;p11)
Endometrial stromal sarcoma t(7;17)(p15;q21)
Inflammatory myofibroblastic tumor t(1;2)(q25;p23)
Giant-cell fibroblastoma t(17;22)(q22;q13)
Extraskeletal myxoid chondrosarcoma t(9;22)(q22;q12)
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growth factor signalling pathway activation and increased
proteolitic and angiogenesis activity contribute to meta-
static progression. Metalloproteinase activity destroys
extracellular matrix promoting loss of cell-cell and cell
matrix interaction, while vascular endothelial growth
factor stimulates angiogenesis and trans-endothelium
migration (Fig. 1a, b), playing a prognostic role in STS
progression. Small tyrosine kinase inhibitors targeting vas-
cular and fibroblast growth factor receptor are presently
available for clinical use in STS subtypes including LMS,
LPS and angiosarcoma. Alternative therapies targeting
Hedgehog, Wnt, and Notch signalling pathways are being
currently developed [21]. In accordance with the CIN-
SARC classification that correlates gene expression related
to genome complexity with metastatic progression [8],
recent studies revealed differences in gene expression
profile that differentiate non-translocation associated
STS into prognostic subsets with a different metastatic
potential [22, 23]. These data support the hypothesis that
a comprehensive genetic analysis is required to stratify
STS patients for therapy and clinical management [24].
Histological and morphological similarities in biologic-
ally heterogenic STS may become a challenge in posing
a differential diagnosis. By using an array approach,
Subramanian et al. [25] demonstrated that the expression
profile of noncoding microRNA (miRNA) was unique
for each type of tumour defining some biological differ-
ences useful in sarcoma classification. It is well known
that mRNAs post-transcriptionally repress gene expres-
sion by recognizing complementary target sites and this
makes them one of the largest families of genome
regulators.
Recently, we identified differentially expressed miRNAs
in a series of poorly differentiated sarcomas and recog-
nized associated chromosome regions and gene targets
that may improve differential diagnosis [26].
Fig. 1 Immunohistochemistry expression of tissue biomarkers in STS. Strong and uniform immunostaining for MMP14 in leiomyosarcoma (a), and for
VEGF in undifferentiated pleomorphic sarcoma (b). PDGF expression in cytoplasm of myxoid liposarcoma (c). Nuclear staining of IGF-1R appeared correlated
to poor outcome in synovial sarcoma (d). (IHC, 20X)
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In STS with simple karyotype, genomic aberrations are
rare and the presence of gene specific alterations as KIT
mutation in GIST and translocations establish constant
diagnostic criteria. Secondary mutations occur during
metastatic progression.
The biological separation between well-differentiated
LPS and myxoid LPS relies on mutually exclusive genetic
alterations. Well-differentiated LPS present amplification
of chromosome region 12q13-15 that address to a thera-
peutic strategy with anti- CDK4 and MDM2 inhibitors,
while myxoid LPS is characterized by chromosomal
translocation t(12;16)(q13;p11) resulting in the FUS-
DDIT3 chimeric gene that plays a critical role in LPS
pathogenesis.
During malignant progression from well-differentiated
LPS and myxoid LPS to de-differentiated and round-cell
histotypes respectively, the secondary genetic mutations
lead to an increased genomic complexity, multiple numer-
ical and structural chromosome aberrations and loss of
specific targets [17]. Immunohistochemical analyses carried
out on myxoid/round cell LPS specimens showed higher
expression of platelet-derived growth factor receptor
(Fig. 1c) in metastatic compared to localized lesions [27].
The interaction between fusion genes and signalling
pathways has been fully studied in synovial sarcoma (SS)
providing indication for combined therapies. The majority
of patients with SYT/SSX1 had overexpression of HER2/
neu oncoprotein associated with poor outcome [28]. In
vitro studies showed high expression of insulin growth
factor receptor IGF-1R and loss of function of PTEN in
SS18-SSX -positive tumours [29, 30]. Since the central role
of SS18-SSX fusion oncoprotein in tumorigenesis involves
its interaction with the transcription factors ATF2 and
TLE1 [31], a treatment with histone deacetylase (HDAC)
inhibitors was suggested [30, 31].
After a retrospective analysis of a series SS patients
[32], we correlated the expression of some potential bio-
markers with clinical parameters and found that nuclear
expression of IGF-1R (Fig. 1d) and chemokine receptor
CXCR4 together with age, tumour size and use of radio-
therapy resulted to be strongly independent adverse
prognostic factors for overall survival [33]. This agrees
with the observation that CXCR4 is implicated in
sarcoma development and is considered a prognostic
marker for poor clinical outcome [34]. Currently, immu-
notherapeutic strategies are promising anticancer effects
in SS and in myxoid/round cell liposarcoma that present
a high expression of immunogenic NY-ESO1, also useful
for the differential diagnosis from other mesenchymal
tumours [35].
Clinical trials using NY-ESO-1-targeted immunother-
apy with genetically modified T-cells reported a clinical
response in malignant melanoma and synovial sarcoma
patients [36].
The link between genetic alterations and therapeutic
strategies has been emphasized in other translocation-
related sarcomas as Ewing’s sarcoma and alveolar RMS
where the respective fusion products, EWS-FLI1 and
PAX3-FOXO1, inducing activation of IGF-1R pathway
stimulate proliferation in vitro and vivo [37]. Although
also fusion negative RMS may present a high IGF
expression, the real effectiveness of small molecules or
antibodies directed at IGF-1R receptor is still under
investigation [38].
In conclusion, emerging genomic and genetic approaches
are being used for a predictive signature for metastases
and clinical outcome [8, 14, 17].
The integration with functional protein expression
will create a system biology analysis able to reveal
common metastatic pathways and new therapeutic target
discovery [14] (Fig. 2).
Role of the imaging
Ultrasound
US plays an important role in detecting soft tissues
masses, and with the use of Power Doppler and the recent
introduction of echographic contrast media it well reveals
the presence of intrinsic flow within the mass and its char-
acteristics improving the Doppler signal. US specificity is
not high, in some cases it is specific in confirming the
hypothesis of a benign lesion like Baker cyst, ganglion,
angioma, lypoma and ossifying myositis. In children son-
ography is in most cases the first imaging evaluation, and
this is particularly useful for small and superficial lesions.
Fig. 2 Research workflow. Data integration for clinical-molecular
classification of STS
Rimondi et al. Cancer Imaging  (2016) 16:13 Page 4 of 13
It is a real time examination that can be carried out with-
out problems of motion artifacts, and this is of utmost im-
portance in children. Furthermore, dynamic scans can be
helpful in the differential diagnosis (for example between
STS and muscular hernias) [39]. Elastosonography is a
new frontier of US, it allows to differentiate the grade of
elasticity of a soft tissue mass compared to the adjacent
tissues by a color map related to the compressibility of the
mass. When elasticity is soft the lesion is generally benign,
when less-soft it is borderline and when no elasticity is
seen the lesion is malignant [40]. US elastosonography,
together with B-mode, power and color Doppler can be a
useful guide not only for biopsy but also in the follow-up
of patients with soft tumours [41] (Fig. 3a-d).
Magnetic resonance imaging: traditional MR
Having almost replaced CT, MRI is the method of
choice for detection, characterization and follow-up of
soft tissues masses. Contrast in soft tissues is of higher
quality allowing an easier detection of the lesion, and
improves delineation of their extent and involvement of
neurovascular structures and medullary bone [41]. Many
STS have a non specific behaviour in T1 and T2-weighted
images. A correct diagnosis can be made only by evaluat-
ing signal intensity, intrinsic lesion features such as site,
size, and growth pattern. Contrast media may help dif-
ferentiate cystic and necrotic components from those
of solid tumour as well as assessing lesion aggressive-
ness. Today in literature there is no concordance about
how traditional MR imaging can precisely differentiate
benign from malignant lesions [42, 43] (Fig. 4a - d).
Magnetic resonance imaging: new MRI techniques
As for bone tumours, newer MRI techniques such as
DCE, DWI, MR Spectroscopy MRS can be used not only
to cope with the problem of differentiating between be-
nign and malignant tumours but also to improve the
possibility of a correct diagnosis [44, 45]. Quantitative
DCE or DCE is a non invasive technique that estimates
the percentage of necrosis in malignant tumours by
comparing pre- and post- treatment examination. This
new technique can identify not only post treatment
Fig. 3 Ultrasound imaging. B-mode and elastosonographic evaluation of intramuscular lipoma (a, b) and osteosarcoma involvement of soft tissue
(c, d), with calcifications included within the latter lesion. In the box of elastosonography (b and d) a colour map ranging from blue to red represents
tissue elasticity; blue is associated with stiffness, red with softness
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necrosis but also early changes during treatment to
modify ineffective therapies. In STS voxels of the nec-
rotic area enhance slowly compared to those of the
remaining viable area. In DCE, although the estimate of
necrosis is obtained from the whole tumour volume,
results are reliable and superimposable to histopatho-
logical evaluation obtained from micron thick sections
of the resected specimen [46]. DCE is also used to differ-
entiate benign from malignant soft tissue lesions [47].
Malignant lesions usually reveal an increased rate of
enhancement of vascularity compared to the benign with
a DCE ratio of 3:1 or 4:1 at the first passage [45, 48].
However, DCE poses a problem with highly cellular
benign tumours that overlap with STS [44].
DWI is an MR technique that is sensitive to the ran-
dom motion of water. Enhancement identifies areas of
inflammatory post-surgical change as well as recurrence
of disease. Unlike morphological MR imaging sequences
and DCE, adds functional information about tissue com-
position without intravenous contrast [46]. DWI tech-
niques depict tissues with signal intensity that vary in
proportion to the average distance by which water mole-
cules are displaced per unit time through the processes
of water self-diffusion. DWI is based on the principle
that diffusion of the water molecules produces a net
dephasing of the spinning protons within a voxel result-
ing in a reduced signal intensity and image brightness.
When examining volume by DWI, signal intensity de-
creases as the average speed of water, which travels
along a temporarily generated magnetic field gradient in-
creases. The quantity of water molecules displaced is
described by the diffusion constant which varies with the
direction. When the distance of water displacement is
the same in all directions diffusion is isotropic. DW im-
ages are direction independent, that is, they are inde-
pendent from the direction along which the magnetic
field is applied. In the human body this occurs in fluids
where mobile water molecules are free to move in all
directions like CSF, brain ventricules or fluids in cystic
lesions. The diffusion constant and average water dis-
placement in these fluids are high and equal in all direc-
tions. The result: strong signal attenuation (dark) on
DWI. In structures where the movement of water mole-
cules is restricted by body structures diffusion is not the
same in all directions, but is direction dependent or
anisotropic. For example, brain water molecules diffuse
faster along the axon with intact myelin sheaths than
perpendicular to them. In other words diffusion signal
loss is higher when the gradient is applied along the
axons axis and lower when applied perpendicular. This
technique was first used to detect acute brain ischemia,
but during the last decade it has become an imaging
biomarker for oncology applied to the entire body.
Today DWI is used to identify and detect tissues where
Fig. 4 Traditional MR imaging. Axial T1 with contrast media and coronal DP fat of huge angiomatosis of the gluteal region and upper right tight.
Either in T1 with contrast or in DP fat weighted image is possible to recognize the huge, mingled, and interspersed, vessels proliferation (a-b).
Metastasis of angiosarcoma of the breast involving either the soft tissue of the gluteal region or the bone of sacral and iliac wing (c-d), axial T1
with contrast media and coronal STIR. In T1 only the soft tissue lesion is hyperintense, in STIR both lesion, soft tissue and bone are hyperintense
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pathologic processes have altered the motion of fluids
outside vessels and capillaries. However, unfortunately,
there is no evidence relating imaging to genetic muta-
tions, VEGF expression, KI 67 expression, and to several
other relevant markers.
DWI is acquired with an echo-planar imaging se-
quence. Dephasing is produced by applying addition
diffusion sensitizing gradients during the image acquisi-
tion cycle. Two magnetic field gradients with the same
polarity are delivered between the excitation pulse and
signal collection to sensibilize the sequence to diffusion
effect. In the middle of the two gradients a 180° RF pulse
is delivered to change the spin phase along the field gra-
dient direction, thus all spins involved and displaced in
the diffusion process, experience a different phase shift.
Protons in water molecules that have moved will be
found in a different position and field strength during
the second gradient. These will not be completely
rephrased and their magnetic moment will no longer
add thus leading to a loss of signal. It is this reduction in
signal intensity that produces a difference in contrast be-
tween the moving molecules (loss of signal intensity:
dark) and not moving molecules (high signal intensity:
bright). Signal attenuation depends on strength and dur-
ation of the gradient pulses, their temporal separation
and the diffusion constant along the direction of the gra-
dient field. The so called b-value quantifies the amount
of signal loss with a given pulse sequence and for a given
diffusion constant i.e. how sensitive a sequence is to dif-
fusion effects. The diffusion constant in biological tissues
can be measured by repeated scanning with different b-
values but identical parameters, in particular unchanged
gradient direction. Observed diffusion constants are
indicated like Apparent Diffusion Coefficents (ADCs) to
differentiate them from the constant of unrestricted
diffusion in pure water. Using ADCs the so called ADC
maps can be built: a grey scale represents the mean
ADC of the corresponding voxel. It is important to note
that an area of viable tumour bright on a DWI image
(for reduced water mobility both for high cellularity and
membrane integrity), will be dark on the corresponding
ADC map (for its lower diffusion constant). Diffusion of
water is in fact more restricted in tumours than in nor-
mal tissues and this on DWI is seen as a high signal
intensity in viable tumours. DWI and ADC maps pro-
vide qualitative and quantitative information about tissue
cellularity and cell integrity. Potentially this is helpful in
identifying not only benign from malignant lesions but
also in revealing necrotic tumours and peri tumoural
edemas from residual viable tumours underscoring the
efficacy of tumour response to therapy. DWI is highly
sensitive to motion, in brain imaging particularly to
rotation or trembling of the head, in trunk imaging to
respiratory motion. To cope with these drawbacks DWI
uses a single shot or multi shot Echo-planar imaging
(EPI). It is fast and renders this techniques less sensitive
to patient motion with the advantages of covering a large
volume, a high signal to noise ratio and a low power de-
position in tissues because several echoes are acquired
after a single excitation pulse. Multishot EPI reduces the
susceptibility artifacts although it increases sensitivity to
motion and scan time, while single shot fast spin-echo
(RARE or HASTE) are less sensitive to susceptibility but
have more limitations in signal to noise ratio and blur-
ring. Sometimes in clinical practice differentiation of
benign or malignant tumours only on ADC quantifica-
tion is not so easy, while non myxoid malignant tumours
show significantly lower ADC values than the benign. In
myxoid tumours the differentiation is not so clear for
the long T2 value of the myxoid extracellular matrix. In
these, ADC values of benign and malignant tumours
overlap: not all malignant tumours present more cellu-
larity than the benign and the benign often have an
extracellular matrix similar to the malignant [46–49].
This happens because conventional ADC values are cal-
culated on a vast range of b value (b 0-600 s/mm2) and
the low b values are sensitive to perfusion determined by
the tumour extracellular water component as opposed
to the use of high b values (300,500, 600 s/mm2) that
are perfusion insensitive so perfusion effects tend to be
canceled. This metric measure is called Perfusion
Insensitive Diffusion Coefficent (PIDC). Costa et al.
propose a PIDC value of 1.1 × 10ˉ3/s to distinguish
malignant from benign lesions: malignant under this
value, benign over. PIDC maps provide more accurate
information about tumour tissue cellularity by minimiz-
ing vascular contributions which are higher in malignant
tumours. Costa and others obtained the highest PIDC
values in myxoid tumours: myxoma, myxoid liposar-
coma, and low grade myxofibrosarcoma show mean
PIDC values of 2.92 x 10-3 mm2/s. This value is due to
the high mucin and low collagen contents of the tumour
that is largely composed of water as confirmed by histo-
logical analysis [50]. When the following features are
present amongst STS we can consider myxoid tumours
and principally myxoid liposarcoma the main diagnostic
hypothesis:
– Features of a cystic lesion on conventional no
contrast MRI.
– Features of a solid lesion on DCE.
– High PIDC values with easy diffusion ADC maps
on DWI.
These three features are very important because myxoid
liposarcomas (about 50 % of all liposarcomas) have less
than 10 % mature fat, that is a low/intermediate signal
intensity on T1-weighted images on conventional MR.
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Small round blue cell tumours (SRBC) are a group of
less differentiated and aggressive embryonal tumours
with similar histologic features and immunochemistry.
They include neuroblastoma, rhabdomyosarcoma, non-
Hodgkin lymphoma, Ewing sarcoma. These tumours show
more restricted diffusion than other STS. For this reason
the differential diagnosis of a tumour with restricted diffu-
sion on ADC maps and very low PIDC values, small
round cell tumours should be the main diagnostic hypoth-
esis, when conventional MRI and CT both with and with-
out contrast give clues to this hypothesis.
Fibroblastic, myofibroblastic and fibrohistiocytic tu-
mours, the most common in all age groups, usually
present low signal intensity in all sequences and a flimsy
to moderate signal intensity increase after contrast on
conventional MRI. These signs together with increased
PIDC values and a restricted diffusion on ADC maps
can help in the differential diagnosis between benign
and malignant masses with morphological features of fi-
brous tumours on conventional MRI. It must be under-
lined that that there are not differences in PIDC values
between benign and intermediate fibrous tumours.
It is also possible to differentiate necrotic masses such
as hematomas and abscesses from necrotic hemorrhagic
in malignant soft tumours by ADC map values both in the
central component and on the peripheral rim. Malignant
tumours for their high cellularity have a more restricted
diffusion on ADC maps in the peripheral rim than in the
central necrotic area. This measure associated to the typ-
ical morphological features of hematomas on conventional
time based T1- and T2- MR images allow to differentiate
benign from malignant necrosis.
Giant Cell Tumour is a bone and soft tissue tumour
presenting low PIDC values and restricted diffusion
on ADC maps. These parameters can be useful in the
diagnosis and management of local recurrences by
revealing differentiation of post-surgical fibrosis from
recurrences [51].
DWI together with conventional MR imaging and CT
can help differentiate between pus-like fluids and serous
cystic fluids. Serous and pure water like necrosis show
active water diffusion and high ADC values, purulent
pus-like fluids show restricted water diffusion and low
ADC values for the high viscosity and cellularity of
pus (Fig. 5a-d) (Fig. 6a-d).
Imaging biomarkers
As in bone sarcomas the knowledge of tumour biology
has been reinforced by advances in the field of molecular
imaging that allow visualization of cell metabolic func-
tions with the use of targets that include cell membrane
receptors and enzymes of intracellular transport. The
signal for imaging origins from the target molecules and
their derivates [46]. A former precursor of functional
Fig. 5 Thirty nine years old girl with a primitive neuroectodermal tumour (PNET). Coronal T1 weighted image (a), Coronal T2 weighted image (b),
DWI B1000 (c-d)
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metabolic imaging was bone scan with 99 metastable
TC-MDP, a nuclear isomer complex introduced in the
early seventies and still in use, nevertheless others are
available today. However, this radiopharmaceutical agent
is more sensitive for primary or secondary lesions of the
bone. Procedures that follow this scheme are positron
emission tomography (PET), MR with molecular MDC,
optical imaging and single photon emission tomog-
raphy (SPECT). Some are used only in research like
optical imaging while others are used pre-clinically and
clinically [52].
Fluorodeoxyglucose positron emission tomography
(FDG-PET) is the method of choice in molecular im-
aging studies, although its role in the workup of soft
tissue tumours is still to be established [53]. FDG-PET
uses positron emitting radionuclides biological tracers
(Carbon 11, Fluorine-18, Technetium-94 and Copper-64).
FDG-PET is used as tracer to study cell metabolism tied
to glucose, frequently altered in neoplasms with an
increased cell turnover. FDG-PET often has a higher sen-
sitivity than tumour markers (for example CEA) present.
In cancer it is used to locate primary tumour when metas-
tases are present and to stage tumour and its response to
therapies. A decrease in FDG uptake indicates improved
survival, while increased or high uptake reflects recur-
rences or a biologically aggressive behaviour. PET/CT
fusion images help match metabolism and morphology
and guide biopsy to target areas that may result in a higher
diagnostic yield [46]. FDG-PET is promising in helping
differentiate benign from malignant lesions, especially in
bone. However, it is important to underline that also in
STS there is some overlap in uptake values [54] (Fig. 7a-f).
The introduction of powerful high field MR scanners,
3 Tesla in clinical practice, up to 7–9 Tesla in clinical
research, has led to two main advantages. The first is a
better spatial resolution that detects smaller lesions
before undetectable. The second is a stronger chemical
shift disparity that makes MRS an even more unique
window to cellular metabolism by non-invasively detect-
ing the concentration of small mobile biological compo-
nents. In vivo MRS allows, either with a single voxel or
multi-voxels study, to identify and quantify the metabo-
lites present within the body volume studied revealing
simultaneously anatomic and physiologic information.
MRS can isolate and examine the body volume without
interference from the nearby structures. It can be used
to measure the level of different metabolites giving
quantitative chemical information reflecting the mo-
lecular composition of a tumour. Changes in meta-
bolite level may be useful indicators of therapeutic
response or of recurrence. Moreover, in molecular
imaging the intrinsic contrast can be improved by the
Fig. 6 Fifty six year old man with a recurrence of an undifferentiated sarcoma grade 3. T1 fat sat weighted image with gadolinium (a), DWI B 1000
(b), spectroscopy (c), Perfusion contrast dynamic curve: 1 muscle, 2 lesion (d)
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use of targeted contrast agents in both experimental
and clinical settings. The evolving field of molecular
imaging requires development of a novel class of MR-
detectable agents that can provide image contrast to target
specific disease processes [55]. However, conventional
DCE and DWI are still of topical interest, and they
provide the most relevant and available MR biomarkers in
today clinical practice and research [56–63].
Tissue-based imaging strategies with and without prior
fluorescent and bioluminescent labelling are currently
employed in basic research providing the simultaneous
discovery of phenotype-related key signatures. Competitive
genomic hybridization array, based on competitive fluores-
cence, recognizes specific chromosome abnormalities asso-
ciated with gain or loss of specific regions harbouring
cancer progression-associated genes [64] and the integra-
tion with mRNA and miRNA array profiling (Fig. 8a)
response [65] and the use of a reporter gene system
may determine activity of a selected gene by visualiz-
ing post-transcriptional and post-translational events
within downstream signalling pathways [66].
The impact of genetic changes on signalling pathway
deregulation may be recognized by molecular imaging
based on mass spectrometry. Mass spectrometry imaging
Fig. 7 Sixteen-year-old, girl with a synovial sarcoma. T1 weighted image (a), T2 weighted image (b), T1 fat sat weighted image with gadolinium
(c), PET Coronal scan (d-e), PET axial scan (f)
Fig. 8 Tissue-based imaging. miRNA array analysis differentiates STS subtypes according to biological features and clinical response (a); wound
healing assay allows to investigate cell-cell, cell-matrix interaction during cell migration to close the “wound” (b)
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(MALDI) technique uses matrix assisted laser desorption
ionization where the sample, often a thin tissue section or
a cell lysate, is moved in two dimensions while the mass
spectrum is recorded. MALDI may identify regions of
the proteome, as well as unmodified or post-translationally
modified proteins or peptides, that today are a new
area of interest for new biomarkers [16, 67, 68]. As
complement of in vitro and ex vivo molecular biology as-
says, molecular imaging is also currently used in research
animals for development of future clinical strategies
providing a in vivo quantitative representation of the
biological processes. By using intravital microscope we
demonstrated that the capacity of fluorescently labelled
LMS cells to invade lymphatic vessels in living mice [69]
is increased by ectopic expression of proteoglycan NG2
involved in tumour cell-environment interaction, found
also overexpressed in advanced/metastatic STS patients
[70]. Deregulation of adhesion and invasion processes
(Fig. 8b), degradation of extracellular matrix and the cap-
ability of tumour cells of migrating across endothelium is
an essential pre-requisite for metastatic spread of tumour
cells and represent one of the multiple hallmarks in
tumour progression [71]. In high-grade STS characterized
by tissue heterogeneity, cellular and molecular imaging
may contribute to improve patient survival through in
vivo detection of prognostic metabolic indicators and
efficacy of treatment.
Conclusions
Translation from laboratory characterization to clinical
application passes through molecular imaging in patients.
Measurement of biological endpoints and visualization of
functional and metabolic changes to malignant transform-
ation and progression provide early detection of disease
and monitoring of therapy efficacy. Thus, the integration of
cell and molecular biology, pathology, bioinformatics, mo-
lecular imaging, new radiological imaging techniques and
clinical features may identify new indicators of disease or
therapeutic effects through the quantitative representation
of biological processes. In particular, this system-biology
analysis may categorize subgroups of distinct endpoints in-
volved in metastatic progression and drug-resistance. Up to
now despite the advances in identifying gene abnormalities
and deregulated pathways few specific endpoints represent
direct targets in sarcoma treatment and chemotherapy
remains the first choice treatment of advanced/metastatic
sarcoma.
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